Tag: renal-cell carcinoma

1. In patients with locoregional clear-cell renal cell carcinoma (RCC) at high risk of recurrence post nephrectomy, those taking sunitinib had a significantly longer median disease-free survival compared to those in the placebo group. 2. The rate of adverse events were greater in patients who took sunitinib compared to those...
1. Galangin caused increased cell death in a renal cancer cell line that is resistant to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), the protein mimicked in certain cancer therapies. 2. The combination of galangin and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) increased cell death in resistant renal carcinoma cells...
1. Computed tomography derived imaging characteristics were correlated with disease specific gene expression to create a radiogenomic based surrogate of molecular assays (SOMA) in patients with clear-cell renal cell carcinoma (CCRCC) which was predictive of disease-specific and stage-independent survival in a validated cohort. 2. Radiogenomic based SOMAs can theoretically be...
Image: PD  1. Pazopanib and sunitinib showed similar efficacy in treating metastatic renal-cell carcinoma as a first-line therapy.  2. Quality-of-life measures generally favored pazopanib. Toxicity profiles were mixed.  Evidence Rating Level: 2 (Good)             Study Rundown: This study demonstrated that pazopanib has more favorable quality-of-life outcomes compared to sunitinib...